About Foundation Medicine
Foundation Medicine offers comprehensive genomic profiling to help match cancer patients with targeted therapies and immunotherapies.
Mission & Story
Mission
Transforming lives in cancer and beyond
Clinical Focus
Medical conditions and clinical areas addressed by Foundation Medicine.
Who It Serves
Milestones & Awards
Recent Milestones
FoundationOne CDx approved as first CGP test with group-based companion diagnostic claim for BRAF inhibitors in melanoma (2021-2022). FoundationOne RNA launched for combined DNA + RNA fusion detection. FoundationOne MRD introduced for early stage breast cancer (2025).
Awards & Recognition
Global leader in approved companion diagnostic indications, first NGS test with group-based CDx claim
Key Partnerships
Social & Media
Follow on
Latest Updates
A New Era of Precision Medicine for Childhood Cancer
A Milestone in Advancing Cancer Care: 1,000 Peer-Reviewed Publications and Counting
A High-Quality Testing Portfolio Grounded in Science – A Research Recap
Ushering in a New Era of Personalized Treatment for Advanced Prostate Cancer
Forging Forward - Our Progress in Biopharmaceutical Partnerships and Outlook for Success in 2025
Company Details
- Founded
- 2009
- Headquarters
- Cambridge, MA, USA
- Employees
- 1001
- Stage
- acquired
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 60 →
23andMe
23andMe uses AI to analyze genetic data and provide personalized health summaries, risk assessments, and wellness recommendations based on genomic insights.
2bPrecise
AI-powered precision medicine platform for personalized treatment recommendations and genomic analysis.
ACT Genomics
AI-powered genomic analysis platform for precision medicine and personalized treatment recommendations.
Adaptive Biotechnologies
Adaptive Biotechnologies uses AI and machine learning to decode the immune system and identify disease-specific immune signatures for diagnosis and personalized treatment.
Ambry Genetics
Ambry Genetics is a leading clinical genetic testing laboratory specializing in hereditary cancer, rare disease, cardiology, and neurology testing. The company provides advanced genetic testing solutions with paired DNA/RNA analysis and comprehensive patient support programs.
Ataraxis
Ataraxis develops AI-native precision medicine tools that predict patient outcomes and treatment response in oncology. Their flagship product, Ataraxis Breast, provides clinically validated prognostic and predictive tests for breast cancer using multi-modal AI analysis of pathology images and clinical data.
Avenda Health
Avenda Health develops Unfold AI, an FDA-cleared artificial intelligence platform that creates 3D cancer estimation maps for prostate cancer. The technology analyzes standard-of-care data (MRI, biopsy, pathology, PSA) to visualize cancer location and extent, helping physicians make more informed treatment decisions and improve patient outcomes.
Base Genomics
Base Genomics appears to be a company in the Precision Medicine & Genomics space, but the scraped website content is empty or inaccessible, preventing detailed analysis of their offerings and target market.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.